A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension

Trial Profile

A Phase 2, Dose-Ranging Study of the Safety and Efficacy of ADX415 Immediate-Release in the Treatment of Essential Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2008

At a glance

  • Drugs ADX 415 (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2008 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Investigational New Drug Application approved by US Food and Drug Administration according to an Addrenex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top